HBIO Harvard Bioscience, Inc. - Common Stock
$7,06
Prezzo · Ago 19, 2026
Fondamentali al Ago 11, 2026
Intervallo 52 sett.
$0–$8
94% of range
Rating Analisti
BUY
8 analysts
Prezzo Obiettivo
$8
+6% upside
P/E (TTM)
-0.6
ROE
-384.8%
Margine di Profitto Netto
-65.5%
Informazioni su Harvard Bioscience, Inc. - Common Stock Panoramica della società da Wikipedia
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
Leggi di più
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.
History
Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.
The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.
In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.
From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.
In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.
The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.
In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).
In 2015 the company acquired HEKA Electronik of Germany.
In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.
In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.
James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.
For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.
In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.
In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.
Products
Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.
Finance
The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.
In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
HBIO Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$7.05
Capitalizzazione di Mercato
$32M
P/E (TTM)
-0.6
EPS (TTM)
$-1.28
Ricavi (TTM)
$87M
Rendimento div.
—
ROE
-384.8%
D/E Debito/Patrimonio
2.6
Intervallo 52 sett.
$0 – $8
HBIO Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$87M
2016-12-31
→
2025-12-31
EPS
$-1.28
2016-12-31
→
2025-12-31
Flusso di cassa libero
$5M
2018-12-31
→
2025-12-31
Margini
-65.5%
2016-12-31
→
2025-12-31
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
HBIO
Mediana dei peer
P/E (TTM)
-0.6
31.3
P/S (TTM)
0.4
0.5
P/B
2.3
1.3
EV / EBITDA
-1.2
—
Price / FCF (Prezzo / FCF)
5.8
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
HBIO
Mediana dei peer
Gross Margin (Margine lordo)
57.7%
47.0%
Operating Margin (Margine Operativo)
-56.1%
—
Net Profit Margin (Margine di Profitto Netto)
-65.5%
-11.4%
ROA
-54.9%
-27.7%
ROE
-384.8%
-58.6%
ROIC
-96.8%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
HBIO
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
2.6
—
Current Ratio (Rapporto corrente)
2.2
1.7
Quick Ratio
1.1
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
HBIO
Mediana dei peer
Revenue YoY (Ricavi YoY)
-8.1%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
-8.6%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
-3.2%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
HBIO
Mediana dei peer
HBIO Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
8 analisti
- Acquisto forte 2 25,0%
- Compra 4 50,0%
- Mantieni 2 25,0%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
1 analisti · 2026-08-16
Basso
$7.50
Alto
$7.50
Target mediano
$7.50
+6,3%
Target medio
$7.50
+6,3%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.05%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $-0.14 | $-0.21 | 0.07% |
| 31 Marzo 2026 | $-0.33 | $-0.63 | 0.30% |
| 31 Dicembre 2025 | $0.00 | $0.36 | -0.36% |
| 30 Settembre 2025 | $0.00 | $0.05 | -0.05% |
| 30 Giugno 2025 | $-0.10 | $-0.10 | 0.00% |
| 31 Marzo 2025 | $-0.10 | $-0.41 | 0.31% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| HYFT | — | — | — | — | — | — |
| BNGO | $16M | -0.3 | -7.4% | -92.6% | -58.8% | — |
| CDT | — | — | — | — | — | — |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M | $109M | $109M | |
| Cost of Revenue | $37M | $39M | $46M | $53M | $51M | $44M | $52M | $58M | $38M | $56M | $60M | $59M | |
| Gross Profit | $50M | $55M | $66M | $61M | $68M | $58M | $64M | $63M | $39M | $48M | $49M | $49M | |
| R&D Expense | $9M | $10M | $12M | $12M | $11M | $9M | $11M | $11M | $6M | $5M | $6M | $5M | |
| SG&A Expense | $18M | $21M | $23M | $24M | $24M | $24M | $23M | $21M | $18M | $21M | $20M | $17M | |
| Operating Expenses | $98M | $61M | $64M | $68M | $66M | $58M | $64M | $62M | $40M | $51M | $50M | $43M | |
| Operating Income | $-49M | $-6M | $2M | $-7M | $2M | $221.0K | $377.0K | $984.0K | $-635.0K | $-3M | $-2M | $7M | |
| Interest Expense | · | · | · | · | · | · | · | $5M | $713.0K | $639.0K | $846.0K | $990.0K | |
| Other Non-op | $-3M | $-325.0K | $-227.0K | $302.0K | $-666.0K | $-806.0K | $-469.0K | $-4M | $-739.0K | $-179.0K | $-1M | $-1M | |
| Pretax Income | $-57M | $-12M | $-3M | $-9M | $-140.0K | $-7M | $-6M | $-8M | $-3M | $-3M | $-4M | $4M | |
| Income Tax | $-686.0K | $740.0K | $859.0K | $337.0K | $148.0K | $518.0K | $-815.0K | $-4M | $-605.0K | $1M | $15M | $2M | |
| Net Income | $-57M | $-12M | $-3M | $-10M | $-288.0K | $-8M | $-5M | $-3M | $-865.0K | $-4M | $-19M | $2M | |
| EPS (Basic) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 | · | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 | |
| EPS (Diluted) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | · | · | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 | |
| Shares (Basic) | 44,391,000 | 43,538,000 | 42,420,000 | 41,413,000 | 40,343,000 | 38,640,000 | 37,813,580 | 36,453,126 | 34,753,325 | 34,211,521 | 33,592,775 | 32,170,683 | |
| Shares (Diluted) | 44,391,000 | 43,538,000 | 42,420,000 | 41,413,000 | 40,343,000 | 38,640,000 | 37,813,580 | 36,453,126 | 34,753,325 | 34,211,521 | 33,592,775 | 33,236,569 | |
| EBITDA | $-49M | $-6M | $2M | $-7M | $2M | $221.0K | $377.0K | $984.0K | $-101.0K | $-3M | $-2M | · |
Stato Patrimoniale 28
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $4M | $4M | $5M | $8M | $8M | $8M | $8M | $6M | $6M | $7M | $14M | |
| Receivables | $16M | $15M | $16M | $17M | $22M | $18M | $21M | $21M | $13M | $16M | $18M | $16M | |
| Inventory | $21M | $23M | $25M | $26M | $28M | $22M | $22M | $25M | $17M | $20M | $22M | $21M | |
| Other Current Assets | $3M | $3M | $4M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | |
| Current Assets | $48M | $45M | $49M | $51M | $62M | $52M | $54M | $58M | $48M | $45M | $51M | $57M | |
| PP&E (Net) | $5M | $5M | $4M | $3M | $3M | $4M | $5M | $6M | $4M | $4M | $6M | $5M | |
| PP&E (Gross) | $23M | $21M | $18M | $18M | $18M | $21M | $20M | $23M | $19M | $19M | $22M | $20M | |
| Accum. Depreciation | $18M | $16M | $14M | $15M | $14M | $17M | $15M | $17M | $16M | $15M | $16M | $15M | |
| Goodwill | $10M | $56M | $57M | $56M | $58M | $59M | $57M | $57M | $36M | $38M | $40M | $40M | |
| Intangibles | $8M | $11M | $16M | $21M | $27M | $33M | $38M | $46M | $10M | $17M | $21M | $21M | |
| Other Non-current Assets | $3M | $3M | $6M | $8M | $5M | $1M | $2M | $2M | $324.0K | $128.0K | $152.0K | $380.0K | |
| Total Assets | $80M | $127M | $137M | $145M | $162M | $156M | $165M | $169M | $109M | $108M | $120M | $136M | |
| Accounts Payable | $4M | $5M | $6M | $6M | $5M | $6M | $5M | $7M | $4M | $6M | $9M | $6M | |
| Accrued Liabilities | · | · | · | · | · | · | $6M | $7M | $4M | $5M | $4M | $4M | |
| Current Liabilities | $22M | $55M | $27M | $23M | $25M | $21M | $25M | $25M | $14M | $15M | $19M | $18M | |
| Capital Leases | $7M | $6M | $5M | $5M | $6M | $7M | $8M | · | · | · | · | · | |
| Deferred Tax | $317.0K | $710.0K | $776.0K | $590.0K | $2M | $2M | $2M | $2M | $3M | $6M | $4M | $1M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $486.0K | $3M | $749.0K | $3M | · | · | · | · | |
| Total Liabilities | $66M | $63M | $64M | $73M | $79M | $80M | $83M | $86M | $28M | $36M | $42M | $40M | |
| Long-term Debt | $36M | $37M | $37M | $47M | $48M | $48M | $54M | $61M | $12M | $14M | $19M | $21M | |
| Total Debt | $36M | $37M | $37M | $47M | $49M | $48M | $50M | $59M | $9M | $11M | $16M | · | |
| Common Stock | $447.0K | $441.0K | $434.0K | $454.0K | $452.0K | $444.0K | $438.0K | $436.0K | $419.0K | $418.0K | $416.0K | $397.0K | |
| Retained Earnings | $-215M | $-158M | $-146M | $-142M | $-133M | $-132M | $-125M | $-120M | $-117M | $-116M | $-112M | $-93M | |
| Treasury Stock | · | · | · | · | $0 | $11M | · | · | · | · | · | · | |
| AOCI | $-12M | $-16M | $-14M | $-15M | $-10M | $-13M | $-13M | $-14M | $-11M | $-17M | $-12M | $-8M | |
| Stockholders' Equity | $14M | $63M | $73M | $72M | $83M | $77M | $82M | $83M | $81M | $72M | $78M | $95M | |
| Liabilities + Equity | $80M | $127M | $137M | $145M | $162M | $156M | $165M | $169M | $109M | $108M | $120M | $136M | |
| Shares Outstanding | 4,471,989 | 44,074,475 | 43,394,509 | 42,081,707 | 41,142,876 | 39,407,080 | 38,188,208 | 37,378,802 | 35,018,478 | 35,018,478 | 33,979,265 | 32,563,256 |
Flusso di cassa 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $4M | $5M | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $3M | $2M | |
| Deferred Tax | $-553.0K | $310.0K | $228.0K | $-498.0K | $-371.0K | $-143.0K | $-398.0K | $-4M | $-2M | $-279.0K | $15M | $1M | |
| Amort. of Intangibles | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $2M | $3M | $3M | $3M | |
| Restructuring | $200.0K | $800.0K | $391.0K | $2M | $1M | $2M | $1M | · | $0 | $-4.0K | $788.0K | $1M | |
| Operating Cash Flow | $7M | $1M | $14M | $1M | $1M | $9M | $8M | $3M | $1M | $5M | $705.0K | $4M | |
| CapEx | $1M | $3M | $2M | $2M | $1M | $1M | $1M | $986.0K | $890.0K | · | · | · | |
| Investing Cash Flow | $-2M | $-1M | $-2M | $-2M | $-1M | $-1M | $-229.0K | $-54M | $-917.0K | $-62.0K | $-8M | $-14M | |
| Debt Issued | $40M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $15M | $-6M | $-4M | $-3M | $-4M | $-67M | $-12M | $-20M | $-5M | $-9M | $-8M | · | |
| Stock Issued | · | · | · | · | · | · | · | $5M | $160.0K | $182.0K | $2M | $2M | |
| Net Stock Activity | · | · | · | · | · | · | · | $5M | $160.0K | $182.0K | $2M | · | |
| Financing Cash Flow | $-1M | $-131.0K | $-12M | $-3M | $-252.0K | $-8M | $-8M | $53M | $-2M | $-5M | $-540.0K | $-1M | |
| Net Change in Cash | $5M | $-175.0K | $-225.0K | $-3M | $-496.0K | $-18.0K | $162.0K | $2M | $137.0K | $-1M | $-7M | $-12M | |
| Taxes Paid | $-98.0K | $-159.0K | $207.0K | $534.0K | $577.0K | $416.0K | $374.0K | $98.0K | $13.0K | · | · | · | |
| Free Cash Flow | $5M | $-1M | $12M | $-438.0K | $67.0K | $8M | $7M | $2M | · | · | · | · | |
| Levered FCF | · | · | · | · | · | · | · | $-995.1K | · | · | · | · |
Redditività 8
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% | 56.9% | 55.4% | 52.3% | 46.7% | 46.3% | 44.8% | · | |
| Operating Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.22% | 0.32% | 0.81% | -0.10% | -2.9% | -1.6% | · | |
| Net Margin | -65.5% | -13.2% | -3.0% | -8.4% | -0.24% | -7.6% | -4.0% | -2.4% | -0.85% | -4.1% | -17.5% | · | |
| Pretax Margin | -66.3% | -12.4% | -2.3% | -8.1% | -0.12% | -7.1% | -4.7% | -6.6% | -2.1% | -2.9% | -3.3% | · | |
| EBITDA Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.22% | 0.32% | 0.81% | -0.10% | -2.9% | -1.6% | · | |
| ROA | -54.9% | -9.4% | -2.4% | -6.2% | -0.18% | -4.9% | -2.8% | -2.1% | -0.80% | -3.8% | -14.9% | · | |
| ROE | -384.8% | -19.3% | -4.6% | -13.2% | -0.36% | -10.2% | -5.9% | -3.6% | -1.1% | -5.8% | -22.0% | · | |
| ROIC | -96.8% | -6.6% | 2.3% | -6.0% | 3.2% | 0.19% | 0.24% | 0.37% | -0.05% | -5.0% | -9.6% | · |
Liquidità e Solvibilità 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 0.8 | 1.8 | 2.2 | 2.4 | 2.5 | 2.1 | 2.7 | 3.4 | 3.1 | 2.6 | · | |
| Quick Ratio | 1.1 | 0.3 | 0.8 | 0.9 | 1.2 | 1.2 | 1.1 | 1.4 | 1.6 | 1.5 | 1.3 | · | |
| Debt / Equity | 2.6 | 0.6 | 0.5 | 0.7 | 0.6 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | · | |
| LT Debt / Equity | 2.6 | 0.0 | 0.4 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | · | |
| Interest Coverage | · | · | · | · | · | · | · | 0.2 | -0.1 | -4.7 | -2.0 | · |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.7 | 0.9 | 0.9 | 0.9 | 0.8 | · | |
| Inventory Turnover | 1.7 | 1.6 | 1.8 | 1.9 | 2.1 | 2.0 | 2.2 | 2.7 | 2.6 | 2.7 | 2.8 | · | |
| Receivables Turnover | 5.6 | 6.1 | 6.8 | 5.9 | 6.0 | 5.3 | 5.5 | 6.9 | 6.4 | 6.3 | 6.5 | · |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -8.1% | -16.1% | -0.96% | -4.7% | 16.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -8.6% | -7.5% | 3.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -3.2% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 13
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M | $109M | $109M | |
| Net Income TTM | $-57M | $-12M | $-3M | $-10M | $-288.0K | $-8M | $-5M | $-3M | $-865.0K | $-4M | $-19M | $2M | |
| Market Cap | $30M | $93M | $232M | $117M | $290M | $169M | $116M | $119M | $116M | $105M | $118M | · | |
| Enterprise Value | $57M | $126M | $265M | $159M | $331M | $209M | $158M | $169M | $119M | $111M | $128M | · | |
| P/E | -0.5 | -7.5 | -66.9 | -12.0 | · | -20.4 | -25.4 | -39.8 | -165.0 | -23.5 | -6.1 | 81.0 | |
| P/S | 0.3 | 1.0 | 2.1 | 1.0 | 2.4 | 1.7 | 1.0 | 1.0 | 1.5 | 1.0 | 1.1 | · | |
| P/B | 2.2 | 1.5 | 3.2 | 1.6 | 3.5 | 2.2 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | · | |
| P / Cash Flow | 4.5 | 64.6 | 16.5 | 101.2 | 229.8 | 18.1 | 14.5 | 41.2 | 109.3 | 19.5 | 167.2 | · | |
| P / FCF | 5.5 | -77.2 | 19.0 | -266.1 | 4329.2 | 20.7 | 17.1 | 62.6 | · | · | · | · | |
| EV / EBITDA | -1.2 | -20.3 | 139.8 | -23.0 | 160.1 | 945.8 | 419.8 | 172.2 | -1176.3 | -37.0 | -74.5 | · | |
| EV / FCF | 10.5 | -104.8 | 21.6 | -363.4 | 4938.0 | 25.6 | 23.2 | 89.3 | · | · | · | · | |
| EV / Revenue | 0.7 | 1.3 | 2.4 | 1.4 | 2.8 | 2.0 | 1.4 | 1.4 | 1.5 | 1.1 | 1.2 | · | |
| Earnings Yield | -191.0% | -13.3% | -1.5% | -8.3% | · | -4.9% | -3.9% | -2.5% | -0.61% | -4.3% | -16.4% | 1.2% |
Conto Economico 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23M | $21M | $24M | $21M | $20M | $22M | $25M | $22M | $23M | $25M | $28M | $25M | $29M | $30M | $28M | $27M | |
| Cost of Revenue | $10M | $9M | $10M | $9M | $9M | $10M | $11M | $9M | $10M | $10M | $12M | $11M | $12M | $12M | $13M | $15M | |
| Gross Profit | $13M | $12M | $14M | $12M | $12M | $12M | $14M | $13M | $13M | $15M | $16M | $15M | $17M | $18M | $16M | $12M | |
| R&D Expense | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $5M | $5M | $4M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $5M | $6M | $5M | $6M | $6M | $6M | |
| Operating Expenses | $14M | $13M | $12M | $12M | $12M | $62M | $14M | $15M | $15M | $17M | $16M | $16M | $16M | $17M | $16M | $16M | |
| Operating Income | $-978.0K | $-1M | $2M | $197.0K | $-819.0K | $-50M | $11.0K | $-2M | $-2M | $-2M | $282.0K | $-933.0K | $796.0K | $2M | $-457.0K | $-4M | |
| Other Non-op | $-125.0K | $-405.0K | $-1M | $-365.0K | $-434.0K | $-193.0K | $516.0K | $-518.0K | $-181.0K | $-142.0K | $-332.0K | $45.0K | $-372.0K | $432.0K | $465.0K | $-179.0K | |
| Pretax Income | $-3M | $-3M | $-3M | $-1M | $-2M | $-51M | $590.0K | $-4M | $-3M | $-4M | $-1M | $-562.0K | $-2M | $1M | $-892.0K | $-5M | |
| Income Tax | $14.0K | $117.0K | $-357.0K | $97.0K | $28.0K | $-454.0K | $572.0K | $311.0K | $-353.0K | $210.0K | $715.0K | $677.0K | $-1M | $585.0K | $774.0K | $-1M | |
| Net Income | $-3M | $-3M | $-3M | $-1M | $-2M | $-50M | $18.0K | $-5M | $-3M | $-5M | $-2M | $-1M | $-980.0K | $622.0K | $-2M | $-3M | |
| EPS (Basic) | $-0.64 | $-0.77 | $-0.06 | $-0.03 | $-0.52 | $-11.42 | $0.01 | $-0.11 | $-0.07 | $-0.11 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | |
| EPS (Diluted) | $-0.64 | $-0.77 | $-0.06 | $-0.03 | $-0.52 | $-11.42 | $0.01 | $-0.11 | $-0.07 | $-0.11 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | |
| Shares (Basic) | 4,526,000 | 4,473,000 | -88,564,000 | 44,556,000 | 4,430,000 | 4,410,000 | -86,964,000 | 43,614,000 | 43,486,000 | 43,402,000 | -84,741,000 | 42,688,000 | 42,354,000 | 42,119,000 | -82,747,000 | 41,637,000 | |
| Shares (Diluted) | 4,526,000 | 4,473,000 | -88,564,000 | 44,556,000 | 4,430,000 | 4,410,000 | -86,964,000 | 43,614,000 | 43,486,000 | 43,402,000 | -85,405,000 | 42,688,000 | 42,354,000 | 42,783,000 | -84,003,000 | 41,637,000 | |
| EBITDA | $-978.0K | $-1M | · | $197.0K | $-819.0K | $-50M | · | $-2M | $-2M | $-2M | · | $-933.0K | $796.0K | $2M | · | $-4M |
Stato Patrimoniale 26
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7M | $7M | $9M | $7M | $7M | $6M | $4M | $5M | $4M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | |
| Receivables | $14M | $15M | $16M | $12M | $12M | $13M | $15M | $13M | $12M | $15M | $16M | $15M | $17M | $18M | $17M | $15M | |
| Inventory | $22M | $22M | $21M | $22M | $22M | $23M | $23M | $26M | $25M | $24M | $25M | $26M | $26M | $27M | $26M | $26M | |
| Other Current Assets | $3M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $4M | $4M | $4M | $5M | $4M | $3M | $6M | |
| Current Assets | $46M | $47M | $48M | $44M | $45M | $45M | $45M | $47M | $46M | $48M | $49M | $50M | $53M | $52M | $51M | $52M | |
| PP&E (Net) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $4M | |
| PP&E (Gross) | · | · | $23M | · | · | · | $21M | · | · | · | $18M | · | · | · | $18M | · | |
| Accum. Depreciation | · | · | $18M | · | · | · | $16M | · | · | · | $14M | · | · | · | $15M | · | |
| Goodwill | $9M | $9M | $10M | $10M | $10M | $9M | $56M | $57M | $57M | $57M | $57M | $56M | $57M | $57M | $56M | $55M | |
| Intangibles | $6M | $7M | $8M | $8M | $9M | $10M | $11M | $12M | $13M | $15M | $16M | $17M | $18M | $20M | $21M | $22M | |
| Other Non-current Assets | $3M | $3M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $5M | $6M | $8M | $6M | $8M | $8M | $8M | |
| Total Assets | $76M | $78M | $80M | $78M | $80M | $80M | $127M | $131M | $129M | $133M | $137M | $140M | $143M | $146M | $145M | $147M | |
| Accounts Payable | $6M | $5M | $4M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | |
| Current Liabilities | $25M | $24M | $22M | $54M | $55M | $56M | $55M | $23M | $23M | $26M | $27M | $24M | $23M | $23M | $23M | $21M | |
| Capital Leases | $6M | $6M | $7M | $7M | $7M | $7M | $6M | $7M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $6M | |
| Deferred Tax | $311.0K | $313.0K | $317.0K | $733.0K | $734.0K | $717.0K | $710.0K | $707.0K | $764.0K | $772.0K | $776.0K | $661.0K | $667.0K | $546.0K | $590.0K | $1M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $892.0K | $1M | $1M | $1M | $420.0K | |
| Total Liabilities | $69M | $68M | $66M | $64M | $64M | $65M | $63M | $66M | $62M | $64M | $64M | $65M | $68M | $71M | $73M | $75M | |
| Long-term Debt | $37M | $36M | $36M | $34M | $35M | $36M | $37M | $38M | $36M | $36M | $37M | $39M | $41M | $44M | $47M | $49M | |
| Total Debt | $37M | $36M | · | · | · | · | · | $38M | $36M | $36M | · | $39M | $42M | $44M | · | $50M | |
| Common Stock | $447.0K | $447.0K | $447.0K | $446.0K | $445.0K | $442.0K | $441.0K | $436.0K | $436.0K | $434.0K | $434.0K | $457.0K | $457.0K | $455.0K | $454.0K | $453.0K | |
| Retained Earnings | $-221M | $-218M | $-215M | $-212M | $-211M | $-208M | $-158M | $-158M | $-153M | $-150M | $-146M | $-144M | $-143M | $-142M | $-142M | $-141M | |
| AOCI | $-12M | $-12M | $-12M | $-12M | $-12M | $-14M | $-16M | $-13M | $-15M | $-15M | $-14M | $-15M | $-14M | $-15M | $-15M | $-16M | |
| Stockholders' Equity | $7M | $10M | $14M | $14M | $16M | $15M | $63M | $65M | $67M | $69M | $73M | $74M | $75M | $74M | $72M | $72M | |
| Liabilities + Equity | $76M | $78M | $80M | $78M | $80M | $80M | $127M | $131M | $129M | $133M | $137M | $140M | $143M | $146M | $145M | $147M | |
| Shares Outstanding | 4,552,305 | 4,510,182 | 44,719,894 | 44,579,665 | 44,531,198 | 44,213,746 | 44,074,475 | 43,616,621 | 43,610,883 | 43,421,251 | 43,394,509 | 42,688,246 | 42,688,246 | 42,190,043 | 42,081,707 | 41,657,688 |
Flusso di cassa 11
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $380.0K | $257.0K | $459.0K | $324.0K | $472.0K | $600.0K | $961.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Amort. of Intangibles | $820.0K | $820.0K | $850.0K | $855.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | |
| Restructuring | $318.0K | $235.0K | $29.0K | $48.0K | $30.0K | $93.0K | $225.0K | $179.0K | $396.0K | $0 | · | · | · | · | $485.0K | $1M | |
| Operating Cash Flow | $325.0K | $-662.0K | $-96.0K | $1M | $3M | $3M | $2M | $-842.0K | $-846.0K | $1M | $4M | $4M | $4M | $2M | $3M | $649.0K | |
| CapEx | $688.0K | $426.0K | $449.0K | $207.0K | $89.0K | $513.0K | $301.0K | $880.0K | $818.0K | $645.0K | $830.0K | $217.0K | $517.0K | $224.0K | $235.0K | $442.0K | |
| Investing Cash Flow | $-916.0K | $-620.0K | $-599.0K | $-348.0K | $-233.0K | $-683.0K | $-466.0K | $-1M | $458.0K | $-225.0K | $-1M | $-401.0K | $-625.0K | $288.0K | $-235.0K | $-442.0K | |
| Net Debt Issued | · | $0 | · | · | · | $-1M | · | · | · | $-3M | · | · | · | $-2M | · | · | |
| Financing Cash Flow | $-38.0K | $-9.0K | $2M | $-1M | $-1M | $-1M | $-1M | $2M | $177.0K | $-1M | $-4M | $-3M | $-2M | $-3M | $-3M | $377.0K | |
| Net Change in Cash | $-595.0K | $-2M | $2M | $-625.0K | $2M | $1M | $-461.0K | $521.0K | $-207.0K | $-28.0K | $-1M | $1M | $535.0K | $-719.0K | $-636.0K | $885.0K | |
| Taxes Paid | $-164.0K | $-5.0K | $-144.0K | $-2.0K | $46.0K | $2.0K | $-474.0K | $184.0K | $105.0K | $26.0K | $39.0K | $53.0K | $249.0K | $-134.0K | $41.0K | $141.0K | |
| Free Cash Flow | · | $-1M | · | · | · | $2M | · | · | · | $758.0K | · | · | · | $2M | · | · |
Redditività 8
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.6% | 59.0% | · | 58.4% | 56.4% | 56.0% | · | 58.1% | 57.2% | 60.3% | · | 58.1% | 58.0% | 61.2% | · | 45.2% | |
| Operating Margin | -4.3% | -5.7% | · | 0.96% | -4.0% | -228.1% | · | -8.5% | -9.0% | -9.3% | · | -3.7% | 2.8% | 5.8% | · | -14.0% | |
| Net Margin | -12.8% | -16.5% | · | -6.0% | -11.2% | -231.2% | · | -21.9% | -12.7% | -19.1% | · | -4.9% | -3.4% | 2.1% | · | -12.7% | |
| Pretax Margin | -12.7% | -15.9% | · | -5.5% | -11.0% | -233.3% | · | -20.4% | -14.2% | -18.3% | · | -2.2% | -7.3% | 4.0% | · | -17.4% | |
| EBITDA Margin | -4.3% | -5.7% | · | 0.96% | -4.0% | -228.1% | · | -8.5% | -9.0% | -9.3% | · | -3.7% | 2.8% | 5.8% | · | -14.0% | |
| ROA | -3.7% | -4.3% | · | -1.2% | -2.2% | -47.3% | · | -3.5% | -2.1% | -3.4% | · | -0.86% | -0.66% | 0.41% | · | -2.3% | |
| ROE | -25.1% | -27.5% | · | -3.1% | -5.5% | -120.4% | · | -6.9% | -4.1% | -6.6% | · | -1.7% | -1.3% | 0.83% | · | -4.6% | |
| ROIC | -2.2% | -2.6% | · | 1.5% | -5.3% | -331.8% | · | -1.9% | -1.8% | -2.3% | · | -1.8% | 0.32% | 0.76% | · | -2.2% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.0 | · | 0.8 | 0.8 | 0.8 | · | 2.1 | 2.1 | 1.9 | · | 2.1 | 2.3 | 2.3 | · | 2.4 | |
| Quick Ratio | 0.8 | 0.9 | · | 0.3 | 0.4 | 0.3 | · | 0.8 | 0.7 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 0.9 | |
| Debt / Equity | 4.9 | 3.6 | · | · | · | · | · | 0.6 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.6 | · | 0.7 | |
| LT Debt / Equity | 4.9 | 3.6 | · | · | · | · | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.6 | · | 0.6 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.6 | |
| Receivables Turnover | 1.7 | 1.5 | · | 1.7 | 1.7 | 1.5 | · | 1.6 | 1.6 | 1.5 | · | 1.7 | 1.7 | 1.6 | · | 1.6 |
Valutazione (TTM) 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $84M | · | $85M | $87M | $91M | · | $95M | $102M | $109M | · | $111M | $115M | $115M | · | $115M | |
| Net Income TTM | $-10M | $-57M | · | $-59M | $-60M | $-63M | · | $-14M | $-10M | $-6M | · | $-5M | $-1M | $-7M | · | $-8M | |
| Market Cap | $28M | $22M | · | $20M | $20M | $25M | · | $117M | $124M | $184M | · | $184M | $234M | $177M | · | $107M | |
| Enterprise Value | $58M | $51M | · | · | · | · | · | $151M | $156M | $216M | · | $217M | $272M | $218M | · | $151M | |
| P/E | -3.1 | -0.4 | · | -0.3 | -0.3 | -0.4 | · | -8.4 | -12.4 | -28.3 | · | -35.8 | -183.0 | -23.3 | · | · | |
| P/S | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.3 | · | 1.2 | 1.2 | 1.7 | · | 1.7 | 2.0 | 1.5 | · | 0.9 | |
| P/B | 3.8 | 2.2 | · | 1.4 | 1.2 | 1.7 | · | 1.8 | 1.8 | 2.7 | · | 2.5 | 3.1 | 2.4 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | 189.4 | 897.9 | · | · | · | |
| P / Cash Flow | · | -33.2 | · | · | · | 8.4 | · | · | · | 131.2 | · | · | · | 97.8 | · | · | |
| P / FCF | · | -20.2 | · | · | · | 10.2 | · | · | · | 242.9 | · | · | · | 111.6 | · | · | |
| EV / EBITDA | -59.5 | -43.5 | · | · | · | · | · | -80.6 | -75.5 | -94.7 | · | -232.8 | 341.4 | 124.5 | · | -40.1 | |
| EV / FCF | · | -46.9 | · | · | · | · | · | · | · | 284.6 | · | · | · | 137.1 | · | · | |
| EV / Revenue | 0.7 | 0.6 | · | · | · | · | · | 1.6 | 1.5 | 2.0 | · | 2.0 | 2.4 | 1.9 | · | 1.3 | |
| Earnings Yield | -31.9% | -251.9% | · | -302.3% | -311.4% | -250.9% | · | -11.9% | -8.1% | -3.5% | · | -2.8% | -0.55% | -4.3% | · | · |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $87M | $94M | $112M | $113M | $119M |
| Margine Lordo % | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% |
| Margine Operativo % | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% |
| Utile netto | $-57M | $-12M | $-3M | $-10M | $-288.0K |
| EPS Diluito | $-1.28 | $-0.28 | $-0.08 | $-0.23 | — |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 2.6 | 0.6 | 0.5 | 0.7 | 0.6 |
| Rapporto corrente | 2.2 | 0.8 | 1.8 | 2.2 | 2.4 |
| Quick Ratio | 1.1 | 0.3 | 0.8 | 0.9 | 1.2 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $5M | $-1M | $12M | $-438.0K | $67.0K |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 9 filer · $5.5M totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 0 (0 vs trimestre precedente) | 0 (-57 vs trimestre precedente) | 2 (+2 vs trimestre precedente) | 0 (-3 vs trimestre precedente) | +90K |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| AMH Equity Ltd | $1.774.844 | 4.047.535 | 32,20% | Azioni |
| Meros Investment Management, LP | $1.125.401 | 182.992 | 20,41% | Azioni |
| VANGUARD GROUP INC | $1.092.570 | 1.633.139 | 19,82% | Azioni |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $879.954 | 143.082 | 15,96% | Azioni |
| TWO SIGMA ADVISERS, LP | $587.578 | 878.556 | 10,66% | Azioni |
| Nuveen Asset Management, LLC | $40.837 | 19.354 | 0,74% | Azioni |
| Point72 Asia (Singapore) Pte. Ltd. | $6.445 | 14.697 | 0,12% | Azioni |
| WOLVERINE TRADING, LLC | $5.102 | 11.600 | 0,09% | Opzione Call |
| Financial Connections Group, Inc. | $0 | 30 | 0,00% | Azioni |
Insider aziendali 35 insider · 14 dirigenti · 18 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| John D Duke | Chief Executive Officer | 20 Marzo 2026 A | 180.000 | 1 | 0 | $25.050 |
| Jeffrey Duchemin | Chief Executive Officer | 07 Luglio 2019 D | 464.528 | 0 | 0 | $0 |
| Mark T Frost | Chief Financial Officer | 20 Marzo 2026 A | 47.500 | 1 | 0 | $25.000 |
| Jennifer Cote | Chief Financial Officer | 19 Marzo 2025 F | 159.019 | 0 | 0 | $0 |
| Michael A. Rossi | Chief Financial Officer | 29 Dicembre 2022 F | 260.540 | 0 | 0 | $0 |
| Kamalam Unninayar | Chief Financial Officer | 07 Marzo 2019 A | 73.858 | 0 | 0 | $0 |
| Bryce Anthony Chicoyne | Chief Financial Officer | 01 Maggio 2007 A | — | 0 | 0 | $0 |
| Mark A Norige | President, Harvard Apparatus | 01 Maggio 2007 A | — | 0 | 0 | $0 |
| David L Strack | President of Subsidiary | 25 Maggio 2005 A | — | 0 | 0 | $0 |
| Kenneth Fletcher Olson | Chief Operating Officer | 29 Dicembre 2021 F | 155.595 | 0 | 0 | $0 |
| Yash Singh | Executive Vice President | 31 Ottobre 2019 A | 39.286 | 0 | 0 | $0 |
| Yong Sun | VP - Commercial Operations | 01 Gennaio 2019 F | 242.805 | 0 | 0 | $0 |
| Yoav Sibony | VP - Global Sales | 03 Agosto 2015 A | 21.582 | 0 | 0 | $0 |
| Paul Bailey | VP, Finance & Admin. | 25 Maggio 2005 A | — | 0 | 0 | $0 |
| Seth Benjamin Benson | Direttore | 09 Giugno 2026 A | 27.556 | 0 | 0 | $0 |
| Katherine A. Eade | Direttore | 09 Giugno 2026 A | 58.669 | 0 | 0 | $0 |
| Robert E. Gagnon | Direttore | 09 Giugno 2026 A | 27.556 | 0 | 0 | $0 |
| William Snider | Direttore | 09 Giugno 2026 A | 48.556 | 2 | 0 | $103.604 |
| Stephen J Denelsky | Direttore | 09 Giugno 2026 A | 37.556 | 1 | 0 | $48.700 |
| James W Green | Direttore | 15 Agosto 2025 D | 2.452.566 | 0 | 0 | $0 |
| Thomas W Loewald | Direttore | 21 Maggio 2024 A | 295.311 | 0 | 0 | $0 |
| Bertrand Loy | Direttore | 21 Maggio 2024 A | 56.575 | 0 | 0 | $0 |
| Alan I Edrick | Direttore | 21 Maggio 2024 A | 273.911 | 0 | 0 | $0 |
| John F Kennedy | Direttore | 23 Marzo 2021 G | 323.344 | 0 | 0 | $0 |
| Susan M. Steele | Direttore | 04 Gennaio 2021 A | 49.400 | 0 | 0 | $0 |
| George Uveges | Direttore | 12 Marzo 2018 M | 142.685 | 0 | 0 | $0 |
| Earl R Lewis | Direttore | 02 Gennaio 2018 A | 477.050 | 0 | 0 | $0 |
| David Green | Direttore | 07 Febbraio 2017 S | 925.571 | 0 | 0 | $0 |
| Neal J Harte | Direttore | 25 Maggio 2016 M | 106.399 | 0 | 0 | $0 |
| Robert A Dishman | Direttore | 28 Aprile 2015 A | 51.055 | 0 | 0 | $0 |
| Chane Graziano | Proprietario del 10% | 07 Novembre 2013 G | 3.005.150 | 0 | 0 | $0 |
| HARVARD BIOSCIENCE INC | Proprietario del 10% | 01 Novembre 2013 J | 0 | 0 | 0 | $0 |
| HSO LIMITED PARTNERSHIP | Proprietario del 10% | 16 Maggio 2008 S | 2.757.257 | 0 | 0 | $0 |
| Thomas Mcnaughton | — | 01 Novembre 2013 J | 171.613 | 0 | 0 | $0 |
| Susan M Luscinski | — | 01 Novembre 2013 J | 469.720 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 5 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider | 23 Marzo 2026 | 15,97% | Deposito iniziale | — | SEC |
| ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 depositi | 22 Giugno 2020 | — | Deposito iniziale | — | SEC |
| HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 depositi | 20 Maggio 2008 | — | Deposito iniziale | — | SEC |
| 14 Dicembre 2007 | — | Deposito iniziale | — | SEC | |
| Persona segnalante non divulgata | 29 Luglio 2002 | — | Deposito iniziale | M&A / vendita | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 2 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.